Constantly improving
ASTar® CE-IVD is the first diagnostic product to reach the market, but there is more going on at Q-linea. The ASTar system is designed to enable rapid and optimal antimicrobial therapy for patients. We’re constantly working to improve and explore new features to the ASTar system, as well as deliver new innovative solutions for faster infectious disease diagnostics to the market.Q-linea AST technology enables
- Resistance reporting in 3 hours – antimicrobial susceptibility results relevant to ESBL screening in 3 hours with a positive predictive value of 100%
- Higher throughput – possibility to analyze up to 50 samples per 24 hours
- Menu expansion – panels for e.g. gram positive bacteria and urine samples
- Semi-automatic – run as both fully automated and semi-automated, directly form clinical samples or isolates
Flexible solution enables future panel extensions
ASTar system can be extended to other types of clinical samples. The modular design of the sample preparation cartridge, in combination with the AST disc, allows for future adaptation to other sample types such as isolates, urine, respiratory and sterile aspirates.
New innovations
World’s first portable culture device
Q-linea also have a technology to utilize the transportation time for blood cultures using portable blood culture cabinets, thereby truly enabling fastest time to result and treatment for all patients with blood infections no matter if you live in the countryside or close to a large hospital.
The portable culture device proposes a solution for how to utilize the transportation time for incubation and detection of pathogenic content, by immediately after blood sampling start the incubation and monitoring of pathogenic content regardless of where in the logistics flow the specimen is (at the ward, in transit etc.). Thus, the total time to optimal antimicrobial therapy result is reduced potentially saving lives for many patients suffering from bacteremia that may lead to sepsis.
Rapid ID and AST
Q-linea has several other disruptive technologies in the pipeline. Q-linea´s bacterial ID and AST technologies for sepsis diagnosis directly from whole blood can be combined into a fully automated sepsis diagnosis system combining both ID and AST, while eliminating the need for prior positive blood culture.
Key elements of the ASTrID concept have already been proven clinically in collaboration with Örebro university hospital.
